Downloaded from: justpaste.it/33j5g
South Africa puts AstraZeneca vaccinations on hold over variant data Prior to widespread circulation of the more contagious variant, the vaccine was showing efficacy of around 75%
By Alexander Winning and Olivia Kumwenda-Mtambo JOHANNESBURG (Reuters) – South Africa will put on hold use of AstraZeneca’s COVID-19 shot in its vaccination programme, after data showed it gave minimal protection against mild-to-moderate infection caused by the country’s dominant coronavirus variant. Health Minister Zweli Mkhize said on Sunday that the government would await advice from scientists on how best to proceed, after a trial showed the AstraZeneca vaccine did not significantly reduce the risk of mild or moderate COVID-19 from the 501Y.V2 variant
that caused a second wave of infections starting late last year. Prior to widespread circulation of the more contagious variant, the vaccine was showing efficacy of around 75%, researchers said. In a later analysis based mostly on infections by the new variant, there was only a 22% lower risk of developing mild-to-moderate COVID-19 versus those given a placebo. Although researchers said the figure was not statistically significant, due to trial design, it is well below the benchmark of at least 50% regulators have set for vaccines to be considered effective against the virus.